You just read:

Adaptive Biotechnologies Receives $2.53 million Phase II SBIR to Develop Test to Identify Cancer Patients at Risk of Death by Infection after Cord Blood Transplants

News provided by

Adaptive Biotechnologies Corporation

Sep 13, 2013, 11:38 ET